The Cost of Silence

December 05, 2018


December 05, 2018

Rashmi Dalai


Rashmi started her career on Wall Street with time spent in both convertible bonds sales and trading at Goldman Sachs and structured derivative products at Lehman Brothers. She left to form her own healthcare consulting practice, and spent over a decade advising a wide range of clients from large university hospitals to start-ups on business and financial strategies. Her role included taking interim COO and CFO positions for clients managing periods of high growth or other business transitions.

In 2007, she began splitting her time between the US and Asia (China, Indonesia, and Singapore) and expanded her consulting business to include advisory on business communications strategies and global thought leadership. Prior to joining The Economist Group, she was Head of Strategic Planning at Weber Shandwick, a global communications and PR firm, in Singapore.

Rashmi holds a Bachelors in International Affairs from Johns Hopkins University and a Masters in International Affairs from Columbia University with a concentration in International Finance and Banking. 

Cardiovascular diseases (CVDs), disorders of the heart and blood vessels, are the leading global cause of death annually.

Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.

As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.

To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.

Download the report to learn more.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week